Characterization of a K562 multidrug-resistant cell line

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
• The K562 human leukemia cell line is a model for studying drug resistance mechanisms.

Purpose of the Study:

• To develop and characterize a daunorubicin-resistant K562 cell line (K562-R).
• To investigate the mechanisms underlying multidrug resistance in K562-R cells.
• To assess the role of calcium channel blockers in reversing drug resistance.

Main Methods:

• In vitro development of daunorubicin-resistant K562 cells (K562-R) through continuous drug exposure.
• Assessment of cross-resistance patterns to anthracyclines and Vinca alkaloids.
• Evaluation of drug resistance reversal using verapamil, a calcium channel blocker.
• Analysis of mRNA expression and protein levels associated with multidrug resistance.
• Drug transport studies to measure intracellular accumulation and retention of daunorubicin.

Main Results:

• K562-R cells exhibited cross-resistance to anthracyclines and Vinca alkaloids.
• Verapamil reversed the cross-resistance phenotype in K562-R cells.
• K562-R cells overexpressed a 4.5-kilobase mRNA encoding a 170,000 Mr membrane glycoprotein implicated in MDR.
• Reduced intracellular accumulation and retention of daunorubicin were observed in K562-R cells.
• Distinct cellular drug pools (rapidly and slowly exchanging) were identified, with a more pronounced rapidly exchanging pool in K562-R cells.
• Overexpression of five cell surface membrane proteins (50,000–210,000 Mr) was associated with MDR development.

Conclusions:

• The K562-R cell line serves as a valuable model for studying anthracycline and Vinca alkaloid resistance.
• Verapamil can overcome certain aspects of multidrug resistance in leukemia cells.
• The identified mRNA and proteins are potential targets for overcoming drug resistance in leukemia.